RESUMO
OBJECTIVE: The purpose of the study was to explore Edaravone and Noscapine in anAlCl3-induced Alzheimer's disease (AD) model. METHODS: Morris Water Maze (MWM), Novel Object Recognition (NOR), andY-maze tests with TNF-α, IL-1, IL-6, amyloid-ß, CAT, SOD and MDAlevels were performed, followed by brain histology. RESULTS: On the probe trial, the MWM demonstrated a decrease in escape latencyfollowed by an increase in the target quadrant. The NOR showeddiscrimination and recognition index scores and Y-maze, revealed arise in spontaneous alterations. TNF-α, IL-1, IL-6, amyloid-ß, CATand MDA levels increased, while SOD levels dropped. The results werefound to be significant for combination full and half doses (***p <0.001, **p < 0.01). The treated group's histology ofbrain revealed mild neurodegeneration with hippocampal pyknoticnuclei. CONCLUSIONS: Thus, Edaravone and Noscapine can be used for thetreatment of AD. .
Abbreviations: AlCl3: Aluminium chloride; AD: Alzheimer's disease; Aß: Amyloid plaques; APP: amyloid precursor protein; BACE 1: Serum beta-secretase 1; GSK3ß: Glycogen synthase kinase 3 ß; CDK 5: cyclin-dependent kinase-5; NFTs: neurofibrillary tangles; ROS: reactive oxygen species; JNK: c Jun N-terminal kinases; MWM: Morris Water Maze; NOR: Novel Object Recognition (NOR); TNF-α: Tumor necrosis factor -α; CAT: Catalase; SOD: Superoxide Dismutase; MDA: Malondialdehyde.
